JP2007517006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517006A5 JP2007517006A5 JP2006546305A JP2006546305A JP2007517006A5 JP 2007517006 A5 JP2007517006 A5 JP 2007517006A5 JP 2006546305 A JP2006546305 A JP 2006546305A JP 2006546305 A JP2006546305 A JP 2006546305A JP 2007517006 A5 JP2007517006 A5 JP 2007517006A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- formula
- amino
- saturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 82
- 125000003545 alkoxy group Chemical group 0.000 claims 49
- 229920006395 saturated elastomer Polymers 0.000 claims 48
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 24
- 125000003282 alkyl amino group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 125000000524 functional group Chemical group 0.000 claims 14
- 125000001153 fluoro group Chemical group F* 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 11
- -1 Amino, carbamoyl Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 125000000335 thiazolyl group Chemical group 0.000 claims 5
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- 125000001589 carboacyl group Chemical group 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000001425 triazolyl group Chemical group 0.000 claims 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 108010090091 TIE-2 Receptor Proteins 0.000 claims 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000002346 iodo group Chemical group I* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- WTVXIBRMWGUIMI-UHFFFAOYSA-N trifluoro($l^{1}-oxidanylsulfonyl)methane Chemical group [O]S(=O)(=O)C(F)(F)F WTVXIBRMWGUIMI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0330001A GB0330001D0 (en) | 2003-12-24 | 2003-12-24 | Compounds |
| GB0416850A GB0416850D0 (en) | 2004-07-29 | 2004-07-29 | Compounds |
| PCT/GB2004/005332 WO2005060969A1 (en) | 2003-12-24 | 2004-12-20 | Pyrimidines with tie2 (tek) activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517006A JP2007517006A (ja) | 2007-06-28 |
| JP2007517006A5 true JP2007517006A5 (enExample) | 2008-02-07 |
Family
ID=34712716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006546305A Pending JP2007517006A (ja) | 2003-12-24 | 2004-12-20 | Tie2(tek)活性のあるピリミジン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080027076A1 (enExample) |
| EP (1) | EP1737462B1 (enExample) |
| JP (1) | JP2007517006A (enExample) |
| AR (1) | AR046996A1 (enExample) |
| AT (1) | ATE402705T1 (enExample) |
| DE (1) | DE602004015509D1 (enExample) |
| ES (1) | ES2309591T3 (enExample) |
| TW (1) | TW200524607A (enExample) |
| UY (1) | UY28700A1 (enExample) |
| WO (1) | WO2005060969A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410913B (de) * | 2001-08-14 | 2003-08-25 | Schelling Anlagenbau Gmbh | Auflagetisch für eine trennsäge mit einem maschinentisch |
| ATE415970T1 (de) * | 2003-12-24 | 2008-12-15 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
| US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| US20080146599A1 (en) * | 2005-02-01 | 2008-06-19 | Astrazeneca Ab | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity |
| US20100048543A1 (en) * | 2005-02-01 | 2010-02-25 | Astrazeneca Ab | Pyrimidine compounds having ties (tek) inhibitory activity |
| GB0502418D0 (en) * | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| JP2008534565A (ja) * | 2005-03-31 | 2008-08-28 | アストラゼネカ アクチボラグ | Tie2阻害活性のあるアミノピリミジン誘導体 |
| AU2013201242B2 (en) * | 2005-12-23 | 2015-05-07 | Takeda Pharmaceuticals U.S.A., Inc. | Bicyclic heteroaryl compounds |
| AU2015210454B2 (en) * | 2005-12-23 | 2016-10-27 | Takeda Pharmaceuticals U.S.A., Inc. | Bicyclic heteroaryl compounds |
| CN101389338B (zh) * | 2005-12-23 | 2013-06-26 | 阿里亚德医药股份有限公司 | 双环杂芳基化合物 |
| HUE047422T2 (hu) | 2005-12-23 | 2020-04-28 | Ariad Pharma Inc | Biciklusos heteroaril vegyületek |
| EA200870514A1 (ru) | 2006-05-08 | 2009-04-28 | Ариад Фармасьютикалз, Инк. | Ацетиленовые гетероарильные соединения |
| ES2555515T3 (es) | 2006-05-08 | 2016-01-04 | Ariad Pharmaceuticals, Inc. | Compuestos de heteroarilo monocíclico |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| EP2671891A3 (en) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| AU2009275957A1 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| AU2009314631B2 (en) | 2008-11-12 | 2014-07-31 | Takeda Pharmaceutical Company Limited | Pyrazinopyrazines and derivatives as kinase inhibitors |
| UY33198A (es) | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
| US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| CA2815506C (en) | 2012-12-12 | 2018-12-11 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| ES2747249T3 (es) * | 2014-07-17 | 2020-03-10 | Sunshine Lake Pharma Co Ltd | Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer |
| US10870647B2 (en) | 2016-06-20 | 2020-12-22 | Daegu-Gyeongbuk Medical Innovation Foundation | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer |
| US11213529B2 (en) | 2017-07-13 | 2022-01-04 | Sunshine Lake Pharma Co., Ltd. | Salt of substituted urea derivative and use thereof in medicine |
| US20210284647A1 (en) * | 2018-07-10 | 2021-09-16 | Voronoibio Inc. | N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamide derivative, and pharmaceutical composition containing same as active ingredient for treating kinase-related diseases |
| CN110272426B (zh) | 2018-07-17 | 2022-05-31 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的炔基(杂)芳环类化合物 |
| EP4105217A4 (en) * | 2020-02-28 | 2023-09-06 | Daegu-Gyeongbuk Medical Innovation Foundation | 3-((8-((1H-PYRAZOL-4-YL))AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION THE CONTAINER AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1261327B1 (en) * | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosine receptor modulators |
| JP5154728B2 (ja) * | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ,インコーポレイテッド | 神経栄養活性を有する置換5−アルキニルピリミジン |
| US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| US20030225273A1 (en) * | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
-
2004
- 2004-12-20 AT AT04806134T patent/ATE402705T1/de not_active IP Right Cessation
- 2004-12-20 EP EP04806134A patent/EP1737462B1/en not_active Expired - Lifetime
- 2004-12-20 US US10/596,740 patent/US20080027076A1/en not_active Abandoned
- 2004-12-20 WO PCT/GB2004/005332 patent/WO2005060969A1/en not_active Ceased
- 2004-12-20 DE DE602004015509T patent/DE602004015509D1/de not_active Expired - Fee Related
- 2004-12-20 JP JP2006546305A patent/JP2007517006A/ja active Pending
- 2004-12-20 ES ES04806134T patent/ES2309591T3/es not_active Expired - Lifetime
- 2004-12-23 UY UY28700A patent/UY28700A1/es not_active Application Discontinuation
- 2004-12-24 TW TW093140595A patent/TW200524607A/zh unknown
- 2004-12-27 AR ARP040104907A patent/AR046996A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517006A5 (enExample) | ||
| JP2007517007A5 (enExample) | ||
| JP5925394B2 (ja) | 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体 | |
| JP6524081B2 (ja) | ジヒドロピリミジン化合物及び医薬におけるその適用 | |
| CN103121996B (zh) | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 | |
| JP5941598B2 (ja) | 5員ヘテロアリールおよびそれらの抗ウイルス剤としての使用 | |
| JP6013375B2 (ja) | キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体 | |
| AU2012210489B2 (en) | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation | |
| KR101551238B1 (ko) | 신규한 hiv 역전사효소 억제제 | |
| US10202390B2 (en) | Heteroaryl substituted aminopyridine compounds | |
| BRPI0720043A2 (pt) | Composto oxadiazol | |
| WO2014181287A1 (en) | Heterocyclyl compounds and uses thereof | |
| AU2007325403A1 (en) | Methods of treating cognitive impairment and dementia | |
| JP2009534406A5 (enExample) | ||
| EP2668183A1 (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| CN102361868A (zh) | 作为1-磷酸-鞘氨醇激动剂的吡唑-1,2,4-噁二唑衍生物 | |
| JP2018526405A5 (enExample) | ||
| RU2007108863A (ru) | Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3 | |
| JP2003529593A5 (enExample) | ||
| JP2015502371A5 (enExample) | ||
| JP7597710B2 (ja) | 置換インドール二量体の化合物 | |
| KR101536488B1 (ko) | 이미다졸 유도체, 그의 제조 방법 및 용도 | |
| CN110612286A (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 | |
| JP7573596B2 (ja) | Irak4阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 | |
| WO2024138201A2 (en) | Selective bet inhibitors and uses thereof |